Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is featured in a BioMedWire editorial examining the urgent need for new treatments for multiple sclerosis (MS), a progressive neurological disease affecting more than 2.9 million people worldwide. The editorial, titled “The Quest to Repair What Multiple Sclerosis Takes Away,” highlights the limitations of existing therapies, which can slow disease progression but cannot stop it completely.
Quantum BioPharma is developing Lucid-MS, a patented, first-in-class drug candidate designed to directly target the myelin sheath damaged by MS. The company said the potential therapy is preparing to advance into Phase 2 clinical trials as it pursues a novel approach to treating the disease. Unlike current treatments that focus on managing symptoms or modulating the immune system, Lucid-MS aims to prevent and reverse myelin degradation, the underlying mechanism of MS, based on preclinical models.
The implications of this announcement are significant for the MS community and the biopharmaceutical industry. If successful, Lucid-MS could represent a paradigm shift in MS treatment, moving from slowing progression to potentially repairing neurological damage. For the 2.9 million people worldwide living with MS, this could mean improved quality of life and slowed disability progression. For the industry, it opens a new therapeutic avenue in neurodegenerative diseases, where disease-modifying treatments are scarce.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of Lucid-MS. The company also retains ownership of 19.84% of Unbuzzd Wellness Inc., with royalty payments of 7% on sales of unbuzzd(TM) until $250 million, then 3% in perpetuity, and retains 100% rights for pharmaceutical and medical uses.
The editorial underscores the critical need for new approaches in MS treatment, as current therapies have limitations. Quantum BioPharma’s Lucid-MS, with its myelin repair mechanism, could address this unmet need. The company’s progress into Phase 2 trials will be closely watched by investors and the medical community. For more information, visit the company’s newsroom at https://ibn.fm/QNTM.
